Enzo Biochem (ENZ) Getting Somewhat Favorable Press Coverage, Report Finds
Media coverage about Enzo Biochem (NYSE:ENZ) has trended somewhat positive on Saturday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enzo Biochem earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 47.0717458860194 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern’s scoring:
- Earnings Scheduled For September 27, 2017 – Benzinga (benzinga.com)
- Enzo Biochem Inc (ENZ) Files 10-K for the Fiscal Year Ended on July 31, 2017 – Nasdaq (nasdaq.com)
- Enzo Biochem’s (ENZ) Q4 2017 Results – Earnings Call Transcript (msn.com)
- Investor Network: Enzo Biochem, Inc. to Host Earnings Call (baystreet.ca)
- Globally the Market of Biomarkers Is Expected to Grow Enormously at the Rate of About 13.3% Till 2022 (sbwire.com)
Shares of Enzo Biochem (NYSE ENZ) traded down 1.60% on Friday, hitting $10.47. 299,788 shares of the company traded hands. The company’s market capitalization is $487.35 million. Enzo Biochem has a 12 month low of $4.88 and a 12 month high of $12.04. The stock’s 50-day moving average price is $11.08 and its 200-day moving average price is $9.80.
ENZ has been the topic of several recent research reports. BidaskClub upgraded shares of Enzo Biochem from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research upgraded shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, June 20th.
About Enzo Biochem
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.